Potent antibodies against SARS-CoV-2 can be produced without T follicular helper cells, suggests study

NewsGuard 100/100 Score

T follicular helper (Tfh) cells are indispensable to the generation of long-lasting immune memory. These are involved in the production and maintenance of germinal centers, which ensure antibody maturation and the creation of effective memory B cells.

There is a correlation in coronavirus disease 2019 (COVID-19) patients between neutralizing antibody titers and the concentration of circulating Tfh cells. However, it is less certain that Tfh concentration can be correlated with disease severity. Some severe COVID-19 cases with deficient Tfh cells due to virus-induced inflammation have been noted, though functions such as antibody class switching and B cell –T cell interactions were found to still occur in the secondary lymphoid organs.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

It has been uncertain whether antibodies produced via this non-canonical pathway are protective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In a new study, recently released as a preprint on the bioRxiv*server, the neutralization potency of these antibodies is compared with those traditionally produced in germinal center-based antiviral responses.

How was the study performed?

Previous studies have demonstrated that CD4+ T-cells are necessary to produce neutralizing antibody titers against SARS-CoV-2, though Tfh CD4+ T-cells are needed to induce high-affinity class-switched antibodies. Non-Tfh cells can promote effective antibody production in some contexts. However, many studies have shown that long-lasting immunity is Tfh dependent, including following the administration of a vaccine where Tfh cell populations indicate vaccine efficacy. To test whether non-Tfh CD4+ T-cells could compensate for Tfh cell loss in viral infection, the group applied SARS-CoV-2 and influenza A to Tfh deficient mice, characterizing the type, affinity, function, and titer of the produced antibodies.

Several types of mice with differently deactivated T-cell production were utilized: Bcl6fl/fl mice, with impaired Tfh cell differentiation; Bcl6fl/flCd4Cre mice, which specifically and completely lack Tfh cells; and Ciita−/− mice, which completely lack all CD4+ T-cells. Human ACE2 was made to overexpress in the respiratory tract of the mice two weeks before application of the virus, and antibodies were collected a further two weeks following infection. It was found that the mice produced high levels of Tfh independent class-switched high-affinity antibodies even in the absence of Tfh cells, most likely produced in the lymph nodes. The formation of germinal center B-cells was severely impaired in the Bcl6fl/fl and Bcl6fl/flCd4Cre mice, though the former still produced high levels of spike protein-specific IgG antibodies. Both mice produced notably more IgG antibodies than the Ciita−/− mice, while spike protein-specific IgM was unaffected by the removal of Tfh cells, both in SARS-CoV-2 and influenza A infection.

Alternative routes to IgG production

The total number of activated CD4+ T-cells was consistent between Bcl6fl/fl and Bcl6fl/flCd4Cre mice, though more of them were T-helper (Th1) cells in the latter, as expected due to the loss of Tfh cell production. Effector molecules ascribed to Tfh cells, CD40L and interleukin-21, were also found to be produced by Th1 cells in a shared manner between the T-cell types in Bcl6fl/fl mice and as the major producer in Bcl6fl/flCd4Cre mice, which completely lack Tfh cells.

The group next analyzed whether Th1 cells are correctly positioned to support B-cells, finding that they are colocalized with B-cells in both Bcl6fl/fl and Bcl6fl/flCd4Cre mice. This suggests that Th1 cells promote antibody production both in the presence or absence of Tfh cells. The antibodies produced by these mice were high-affinity towards the spike protein and receptor-binding domain (RBD) of SARS-CoV-2, reaching a peak 14 days post-infection and persisting to at least 49 days, while IgG antibodies produced in Ciita−/− mice were much lower affinity and did not persist for nearly as long.

The Tfh-independently (Bcl6fl/flCd4Cre mice) produced antibodies lacked the IgG1/IgG3 subclasses. In tests, the neutralization potency of Bcl6fl/fl mice sera was seen to be higher, mainly due to the higher titers of spike protein-specific IgG. However, the neutralization potency of each individual antibody was found to be greater in Bcl6fl/flCd4Cre mice sera when normalizing the titer levels. Finally, the group tested the neutralization capacity of the collected antibodies against the SARS-CoV-2 variant of concern B.1.351, finding that efficacy was maintained both in antibodies produced via the Tfh cell route or independently of it.

IgG1 and IgG2 bind with Fc receptors, key immune regulatory modulators, with the latter being essential to viral clearance in vitro. As Th1 cells could produce IgG2, the group expects sufficient levels of antibodies with Fc effector function to be produced, even in the absence of Tfh cells. Unlike SARS-CoV-2, influenza failed to produce high-affinity Tfh independent antibodies. Profiling the antibodies generated against SARS-CoV-2 by Th1 revealed that most epitopes were towards highly conserved regions across human coronaviruses, which the authors suggest could explain the possible lesser need for antibody affinity maturation in those generated by Th1 in the lymph nodes.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:
  • Preliminary scientific report. Jennifer S. Chen,  Ryan D. Chow, Eric Song, Tianyang Mao, Benjamin Israelow, Kathy Kamath, Joel Bozekowski, Winston A. Haynes, Renata B. Filler, Bridget L. Menasche, Jin Wei, Mia Madel Alfajaro, Wenzhi Song, Lei Peng, Lauren Carter, Jason S. Weinstein, Uthaman Gowthaman,  Sidi Chen, Joe Craft, John C. Shon,  Akiko Iwasaki, Craig B. Wilen, Stephanie C. Eisenbarth. High-affinity, neutralizing antibodies to SARS-CoV-2 can be made in the absence of T follicular helper cells. bioRxiv preprint server. doi: https://doi.org/10.1101/2021.06.10.447982, https://www.biorxiv.org/content/10.1101/2021.06.10.447982v1.  
  • Peer reviewed and published scientific report. Chen, Jennifer S., Ryan D. Chow, Eric Song, Tianyang Mao, Benjamin Israelow, Kathy Kamath, Joel Bozekowski, et al. 2022. “High-Affinity, Neutralizing Antibodies to SARS-CoV-2 Can Be Made without T Follicular Helper Cells.” Science Immunology 7 (68). https://doi.org/10.1126/sciimmunol.abl5652https://www.science.org/doi/10.1126/sciimmunol.abl5652.

Article Revisions

  • Apr 10 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Michael Greenwood

Written by

Michael Greenwood

Michael graduated from the University of Salford with a Ph.D. in Biochemistry in 2023, and has keen research interests towards nanotechnology and its application to biological systems. Michael has written on a wide range of science communication and news topics within the life sciences and related fields since 2019, and engages extensively with current developments in journal publications.  

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Greenwood, Michael. (2023, April 10). Potent antibodies against SARS-CoV-2 can be produced without T follicular helper cells, suggests study. News-Medical. Retrieved on April 23, 2024 from https://www.news-medical.net/news/20210615/Potent-antibodies-against-SARS-CoV-2-can-be-produced-without-T-follicular-helper-cells-suggests-study.aspx.

  • MLA

    Greenwood, Michael. "Potent antibodies against SARS-CoV-2 can be produced without T follicular helper cells, suggests study". News-Medical. 23 April 2024. <https://www.news-medical.net/news/20210615/Potent-antibodies-against-SARS-CoV-2-can-be-produced-without-T-follicular-helper-cells-suggests-study.aspx>.

  • Chicago

    Greenwood, Michael. "Potent antibodies against SARS-CoV-2 can be produced without T follicular helper cells, suggests study". News-Medical. https://www.news-medical.net/news/20210615/Potent-antibodies-against-SARS-CoV-2-can-be-produced-without-T-follicular-helper-cells-suggests-study.aspx. (accessed April 23, 2024).

  • Harvard

    Greenwood, Michael. 2023. Potent antibodies against SARS-CoV-2 can be produced without T follicular helper cells, suggests study. News-Medical, viewed 23 April 2024, https://www.news-medical.net/news/20210615/Potent-antibodies-against-SARS-CoV-2-can-be-produced-without-T-follicular-helper-cells-suggests-study.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New vaccine promises broad protection against SARS-CoV-2 and other sarbecoviruses